Publisher Correction: Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer

被引：0
|
作者：
Mathilde Louise Gehrchen [1 ]
Tobias Berg [1 ]
Rasmus Garly [2 ]
Maj-Britt Jensen [1 ]
Saskia Eßer-Naumann [1 ]
Jeanette Dupont Rønlev [3 ]
Hanne Melgaard Nielsen [4 ]
Ann Knoop [5 ]
Iben Kümler [1 ]
机构：
[1] Copenhagen University Hospital,Danish Breast Cancer Group, Department of Oncology
[2] Rigshospitalet,Department of Oncology
[3] Copenhagen University Hospital,Department of Oncology
[4] Rigshospitalet,Department of Oncology
[5] Næstved Hospital,Department of Oncology
[6] University Hospital of Odense,Department of Oncology
[7] Aarhus University Hospital,Department of Clinical Medicine, Faculty of Health and Medical Sciences
[8] Herlev and Gentofte University Hospital,undefined
[9] University of Copenhagen,undefined
来源：
BJC Reports | / 2卷 / 1期
关键词：
D O I：
10.1038/s44276-024-00083-5
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer
    Mathilde Louise Gehrchen
    Tobias Berg
    Rasmus Garly
    Maj-Britt Jensen
    Saskia Eßer-Naumann
    Jeanette Dupont Rønlev
    Hanne Melgaard Nielsen
    Ann Knoop
    Iben Kümler
    BJC Reports, 2 (1):
  • [2] CDK4/6 inhibitors in metastatic breast cancer: An Italian real-world experience
    Pantano, F.
    Scafetta, R.
    Curigliano, G.
    Criscitiello, C.
    Botticelli, A.
    Caputo, R.
    D'Auria, G.
    Garrone, O.
    Gori, S.
    Meattini, I.
    Minelli, M.
    Piras, M.
    Rossi, L.
    Stucci, L. S.
    Tagliaferri, B.
    Toss, A.
    Vernieri, C.
    Vici, P.
    Tonini, G.
    Santini, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S346 - S347
  • [3] Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania
    Miron, Andreea-Iuliana
    Anghel, Alexandra-Valentina
    Barnonschi, Andrei-Alexandru
    Mitre, Ruxandra
    Liscu, Horia-Dan
    Gainariu, Estera
    Patru, Raluca
    Coniac, Simona
    DIAGNOSTICS, 2023, 13 (11)
  • [4] CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset
    Buller, William
    Pallan, Lalit
    Chu, Teresa
    Khoja, Leila
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (08) : 1825 - 1835
  • [5] Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia
    Low, Jia Li
    Lim, Elaine
    Bharwani, Lavina
    Wong, Andrea
    Wong, Karmen
    Ow, Samuel
    Lim, Siew Eng
    Lee, Matilda
    Choo, Joan
    Lim, Joline
    Chan, Gloria
    Walsh, Robert John
    Muthu, Vaishnavi
    Ngoi, Natalie
    Chong, Wanqin
    Tan, Sing Huang
    Lee, Soo Chin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [6] Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population
    Chen, Bo-Fang
    Tsai, Yi-Fang
    Chao, Ta-Chung
    Lien, Pei-Ju
    Lin, Yen-Shu
    Feng, Chin-Jung
    Chen, Yen-Jen
    Cheng, Han-Fang
    Liu, Chun-Yu
    Lai, Jiun-, I
    Tseng, Ling-Ming
    Huang, Chi-Cheng
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [7] Real-world Indian scenario of CDK4/6 inhibitors (palbociclib and ribociclib) with endocrine therapy in upfront hormone positive metastatic breast cancer.
    Gogia, Ajay
    Arora, Shalabh
    Choudhary, Priyanshu
    Kumar, Rakesh
    Thulkar, Sanjay
    Deo, S. V. S.
    Sharma, Dayanand
    Bhatnagar, Sushma
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] REAL-WORLD USE OF CDK4/6 INHIBITORS - EFFECTIVENESS AND SUBSEQUENT THERAPIES
    Stativko, Olesia
    Khachaturian, Elina
    Tsareva, Elena
    Shangina, Irina
    Maystrenko, Ksenia
    Antonova, Tatiana
    Pokataev, Ilya
    BREAST, 2023, 71 : S59 - S59
  • [9] Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors
    Kanjanapan, Yada
    Anderson, Wayne
    Smith, Mirka
    Green, Jenny
    Chalker, Elizabeth
    Craft, Paul
    CLINICAL BREAST CANCER, 2025, 25 (02)
  • [10] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR +/HER2-Breast Cancer at a Single Cancer Center
    Kovacevic, M. Milovic
    Bobic, S.
    Karaferic, A.
    Pavlovic, L.
    Matovic, M.
    BREAST, 2023, 68 : S46 - S46
12345